Altinicline (SIB-1508Y) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, although its current status is unclear.
Wagner, Florence F.; Comins, Daniel L. (2006). "Expedient Five-Step Synthesis of SIB-1508Y from Natural Nicotine". The Journal of Organic Chemistry 71 (22): 8673. DOI:10.1021/jo0616052. PMID 17064057.